Clinical Trial Update: NAG-excretion During Cardiopulmonary Bypass

View source ↗

Summary

A clinical trial evaluating urinary N-acetyl-β-D-glucosaminidase (NAG) excretion during cardiopulmonary bypass has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Injury

Snippet

Sponsor: Sahlgrenska University Hospital | Conditions: Renal Impairment | Status: COMPLETED